Rankings
▼
Calendar
URGN Q1 2025 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena
URGN
UroGen Pharma Ltd.
$927M
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$20M
+7.8% YoY
Gross Profit
$18M
88.5% margin
Operating Income
-$37M
-182.3% margin
Net Income
-$44M
-216.5% margin
EPS (Diluted)
$-0.92
QoQ Revenue Growth
-17.5%
Cash Flow
Operating Cash Flow
-$42M
Free Cash Flow
-$42M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$248M
Total Liabilities
$294M
Stockholders' Equity
-$46M
Cash & Equivalents
$104M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$20M
$19M
+7.8%
Gross Profit
$18M
$17M
+5.1%
Operating Income
-$37M
-$26M
-43.4%
Net Income
-$44M
-$32M
-35.8%
Revenue Segments
Jelmyto
$20M
100%
← FY 2025
All Quarters
Q2 2025 →